Noteworthy Price Action: Taro Pharmaceutical Industries Ltd. Just Recorded A Sigfniciant Decline

Noteworthy Price Action: Taro Pharmaceutical Industries Ltd. Just Recorded A Sigfniciant Decline

The stock of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) is a huge mover today! About 188,485 shares traded hands. Taro Pharmaceutical Industries Ltd. (NYSE:TARO) has declined 22.89% since March 11, 2016 and is downtrending. It has underperformed by 28.35% the S&P500.
The move comes after 7 months negative chart setup for the $4.53 billion company. It was reported on Oct, 14 by We have $97.37 PT which if reached, will make NYSE:TARO worth $317.10 million less.

Analysts await Taro Pharmaceutical Industries Ltd. (NYSE:TARO) to report earnings on November, 1.

According to Zacks Investment Research, “Taro Pharmaceutical Industries is engaged in the production, research and development, and marketing of prescription and over-the-counter pharmaceutical products, with a focus on generic products. In addition to the production of finished dosage form drugs, they also synthesize the pharmaceutical chemicals used in their production. Products are sold through wholesalers, generic drug distributors, drug store chains, mass merchandisers, HMOs, food stores, pharmacies and hospitals.”

More notable recent Taro Pharmaceutical Industries Ltd. (NYSE:TARO) news were published by: which released: “RSI Alert: Taro Pharmaceutical Industries (TARO) Now Oversold” on August 24, 2016, also with their article: “Taro Pharmaceutical Industries Becomes Oversold (TARO)” published on October 11, 2016, published: “Taro Pharma: Seeking A Catalyst” on July 28, 2016. More interesting news about Taro Pharmaceutical Industries Ltd. (NYSE:TARO) were released by: and their article: “Invest Like Vailshire: Taro Pharmaceutical Industries Ltd Is A Hidden Gem” published on September 30, 2015 as well as‘s news article titled: “Taro Pharmaceutical Industries’ (TARO) CEO Kal Sundaram on Q4 2016 Results …” with publication date: May 27, 2016.

TARO Company Profile

Taro Pharmaceutical Industries Ltd. (Taro), incorporated on June 3, 1959, is a science pharmaceutical company. The Firm develops, makes and markets prescription (Rx) and over-the-counter (OTC) pharmaceutical products, primarily in the United States, Canada and Israel. Taro also develops and makes active pharmaceutical ingredients (APIs), primarily for use in its finished dosage form products. The Company’s primary areas of focus include semi-solids formulations, such as creams and ointments, and other dosage forms, such as liquids, capsules and tablets, primarily in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment